Table 3.
The analysis of in-hospital laboratory test, echocardiography, and electrocardiograph monitoring results
| All (n = 213) |
Genotype | P value | |||
|---|---|---|---|---|---|
| Arg389Arg (n = 140) | Arg389Gly (n = 46) | Gly389Gly (n = 27) |
|||
| LDL-C | 2.96 ± 0.69 | 2.93 ± 0.67 | 3.05 ± 0.72 | 2.96 ± 0.77 | 0.585 |
| Peak cTnT | 3.62 ± 2.27 | 4.00 ± 2.43 | 2.92 ± 1.67 | 2.82 ± 1.82 | 0.003 |
| Peak pro-BNP | 1730.09 (1013.51,3029.37) | 1942.37 (1223.19,4206.59) | 1530.47 (798.89,2359.81) | 1604.57 (798.05,1884.79) | 0.047 |
| EF% | 54.76 ± 4.88 | 54.13 ± 4.94 | 55.28 ± 5.21 | 57.11 ± 2.87 | 0.010 |
| Ventricular tachycardia | 33 (15.49%) | 27 (19.29%) | 6 (13.04%) | 0 (0.00%) | 0.017 |
| PVC | 138 (64.79%) | 98 (70.00%) | 29 (63.04%) | 11 (40.74%) | 0.013 |
| Frequent PVC | 74 (34.74%) | 57 (40.71%) | 12 (26.09%) | 5 (18.52%) | 0.031 |
| Bigeminy | 28 (13.15%) | 22 (12.71%) | 4 (8.70%) | 2 (7.41%) | 0.415 |
| Trigeminy | 61 (28.64%) | 42 (30.00%) | 15 (32.61%) | 4 (16.81%) | 0.222 |
| Polymorphic PVC | 7 (3.29%) | 4 (2.86%) | 2 (4.35%) | 1 (3.70%) | 0.613 |
| PVC time >48 h | 28 (13.15%) | 21 (15.00%) | 5 (10.87%) | 2 (7.41%) | 0.565 |
CTnT, cardiac troponin T; EF, ejection fraction; PVC, premature ventricular contraction.